| Literature DB >> 33209045 |
Ning Chen1,2, Iram Faqir Muhammad2, Zhibin Li3, Peter M Nilsson2,4, Yan Borné2.
Abstract
OBJECTIVE: To explore the longitudinal, as well as sex-specific, associations between circulating uric acid (UA) and diabetes incidence.Entities:
Keywords: cohort study; diabetes incidence; longitudinal; stratified analysis; uric acid
Year: 2020 PMID: 33209045 PMCID: PMC7669519 DOI: 10.2147/DMSO.S273387
Source DB: PubMed Journal: Diabetes Metab Syndr Obes ISSN: 1178-7007 Impact factor: 3.168
Baseline Characteristics Stratified by the Tertiles of Uric Acid Level and Incident Diabetes (n=3140)
| Variables | Baseline Uric Acid | Incident Diabetes | |||||
|---|---|---|---|---|---|---|---|
| Tertile 1 | Tertile 2 | Tertile 3 | P-value | Yes | No | P-value | |
| N (%) | 1043 (33.2%) | 1056 (33.6%) | 1041 (33.2%) | 315 (10.0%) | 2825 (90.0%) | ||
| Age (years) | 71.44±5.54 | 72.36±5.56 | 73.21±5.64 | <0.001 | 71.84±5.85 | 72.39±5.60 | 0.101 |
| Current smoker (%) | 12.3% | 10.0% | 7.6% | <0.001 | 10.7% | 9.8% | 0.123 |
| BMI (kg/m2) | 25.16±3.78 | 26.42±3.80 | 28.10±4.50 | <0.001 | 28.53±4.70 | 26.34±4.10 | <0.001 |
| Waist circumference (cm) | 87.61±11.59 | 90.97±11.48 | 95.30±11.91 | <0.001 | 97.45±12.10 | 90.61±11.88 | <0.001 |
| Systolic blood pressure (mmHg) | 142.21±19.14 | 142.91±18.65 | 143.04±19.02 | 0.317 | 147.13±20.06 | 142.23±18.75 | <0.001 |
| Use of lipid lowering drugs, % | 19.6% | 25.6% | 33.4% | <0.001 | 36.2% | 25.1% | <0.001 |
| Use of ACE inhibitors (%) | 14.2% | 18.8% | 30.5% | <0.001 | 25.1% | 20.7% | 0.072 |
| Triglyceride (mmol/L) | 0.91±0.39 | 1.05±0.57 | 1.23±0.58 | <0.001 | 1.27±0.60 | 1.04±0.52 | <0.001 |
| HDL-cholesterol (mmol/L) | 1.54±0.44 | 1.46±0.45 | 1.35±0.39 | <0.001 | 1.29±0.38 | 1.47±0.44 | <0.001 |
| LDL-cholesterol (mmol/L) | 3.42±0.87 | 3.40±0.90 | 3.33±0.97 | 0.026 | 3.21±0.87 | 3.40±0.92 | 0.001 |
| 0-h PG (OGTT, mmol/L) | 5.72±0.76 | 5.79±0.67 | 5.95±0.74 | <0.001 | 6.70±1.10 | 5.72±0.60 | <0.001 |
| 2-h PG (OGTT, mmol/L) | 6.67±2.05 | 6.90±2.97 | 7.56±2.37 | <0.001 | 10.05±4.74 | 6.67±1.87 | <0.001 |
| CRP (mg/L) (median (P25-P75))* | 1.10 (0.10–2.30) | 1.40 (0.70–2.80) | 2.10 (0.97–3.90) | <0.001 | 2.10 (1.00–4.10) | 1.40 (0.68–2.90) | <0.001 |
| Uric acid (µmol/L) | 233.74±35.88 | 297.55±31.09 | 383.45±59.37 | <0.001 | 328.34±77.73 | 302.21±74.56 | <0.001 |
Notes: *Median (P25–P75) is presented for CRP. All other values were means ± standard deviation or percentages (%).
Abbreviations: BMI, body mass index; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein cholesterol; OGTT, oral glucose tolerance test; UA, uric acid.
Incidence Rate (1/1000 Person-Years) of Diabetes Stratified by Sex-Specific Tertiles of Baseline Uric Acid (n=3140)
| Baseline Uric Acid | N | Person-Years | Number of Incident Diabetes | Diabetes Incidence Rate | |
|---|---|---|---|---|---|
| (1/1000 Person-Years) | |||||
| Tertiles of UA | |||||
| Tertile 1 | 1043 | 9120.99 | 72 | 7.89 | |
| Tertile 2 | 1056 | 9068.91 | 86 | 9.48 | |
| Tertile 3 | 1041 | 8671.69 | 157 | 18.11 | |
| P-value | <0.001 | ||||
| Tertiles of UA | |||||
| Tertile 1 | 412 | 3527.01 | 40 | 11.34 | |
| Tertile 2 | 409 | 3397.50 | 35 | 10.30 | |
| Tertile 3 | 406 | 3327.56 | 63 | 18.93 | |
| P-value | <0.001 | ||||
| Tertiles of UA | |||||
| Tertile 1 | 631 | 5593.98 | 32 | 5.72 | |
| Tertile 2 | 647 | 5671.41 | 51 | 8.99 | |
| Tertile 3 | 635 | 5344.13 | 94 | 17.59 | |
| P-value | <0.001 | ||||
Abbreviation: UA, uric acid.
Figure 1(A) Cumulative incidence of diabetes across the tertiles of baseline uric acid in total sample. (B) Cumulative incidence of diabetes in relation to the tertiles of baseline uric acid in men. (C) Cumulative incidence of diabetes in relation to the tertiles of baseline uric acid in women.
Figure 2Receiver operating characteristic (ROC) curve of the prediction of diabetes incidence.
Adjusted Hazards Ratios (HRs) with Associated 95% Confidence Interval (CI) for Incident Diabetes in Relation to Baseline Circulating Uric Acid
| Variables | Baseline Uric Acid† | Tertiles of Baseline Uric Acid‡ | ||||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | Tertile 1 | Tertile 2 | Tertile 3 | P value for Trend Test | |||
| HR | HR (95% CI) | P value | HR (95% CI) | P value | ||||
| Model 1 (n=3140) | 1.38 (1.23–1.54) | <0.001 | 1.00 | 1.30 (0.95–1.78) | 0.100 | 2.30 (1.74–3.05) | <0.001 | <0.001 |
| Model 2 (n=3140) | 1.22 (1.08–1.37) | 0.002 | 1.00 | 1.21 (0.86–1.70) | 0.270 | 1.79 (1.30–2.47) | <0.001 | <0.001 |
| Model 3 (n=2422) | 1.22 (1.08–1.39) | 0.002 | 1.00 | 1.14 (0.79–1.64) | 0.500 | 1.74 (1.24–2.45) | 0.002 | <0.001 |
| Model 1 (n=1227) | 1.26 (1.07–1.49) | 0.005 | 1.00 | 0.98 (0.62–1.55) | 0.931 | 1.49 (0.99–2.22) | 0.055 | 0.045 |
| Model 2 (n=1227) | 1.26 (1.05–1.50) | 0.013 | 1.00 | 0.99 (0.61–1.64) | 0.991 | 1.46 (0.93–2.30) | 0.100 | 0.077 |
| Model 3 (n=949) | 1.21 (1.01–1.47) | 0.046 | 1.00 | 0.94 (0.55–1.62) | 0.835 | 1.40 (0.85–2.29) | 0.185 | 0.145 |
| Model 1 (n=1913) | 1.49 (1.29–1.73) | <0.001 | 1.00 | 2.30 (1.74–3.05) | 0.022 | 3.42 (2.28–5.13) | <0.001 | <0.001 |
| Model 2 (n=1913) | 0.99 (0.82–1.18) | 0.882 | 1.00 | 0.92 (0.55–1.54) | 0.742 | 1.25 (0.76–2.04) | 0.382 | 0.219 |
| Model 3 (n=1473) | 1.04 (0.85–1.26) | 0.722 | 1.00 | 0.92 (0.55–1.53) | 0.742 | 1.25 (0.76–2.04) | 0.382 | 0.199 |
Notes: †Hazards ratios (HR) and 95% confidence interval (CI) was expressed by per SD increase of serum uric acid. ‡HR and 95% CI was expressed by the first tertile of serum uric acid as the reference. Model 1: Adjusted for age and sex. Model 2: Model 1 plus waist circumference, smoking habits, systolic blood pressure, HDL cholesterol, triglycerides, use of lipid lowering drugs and fasting glucose. Model 3: Model 2 plus C-reactive protein.